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Abstract
Background: To demonstrate the potential of Population Impact Measures in helping to prioritise
alternative interventions for psychiatry, this paper estimates the number of relapses and hospital
readmissions prevented for depression and schizophrenia by adopting best practice
recommendations. The results are designed to relate to particular local populations.
Methods:  Literature-based estimates of disease prevalence, relapse and re-admission rates,
current and best practice treatment rates, levels of adherence with interventions and relative risk
reduction associated with different interventions were obtained and calculations made of the
Number of Events Prevented in your Population (NEPP).
Results: In a notional population of 100,000 adults, going from current to 'best' practice for
different interventions, the number of relapses prevented in the next year for schizophrenia were
6 (increasing adherence to medication), 23 (family intervention), 43 (relapse prevention), and 44
(early intervention); and for depression the number of relapses prevented in the next year were
100 (increasing care management), 227 (continuing treatment with antidepressants), 279
(increasing rate of diagnosis), and 325 (Cognitive Behaviour Therapy). Hospital re-admissions
prevented in the next year for schizophrenia were 6 (increasing adherence to medication), 36
(relapse prevention) and 40 (early intervention).
Conclusion: Population Impact measures provide the possibility for a policy-maker to see the
impact of a new intervention on the population as a whole, and to compare alternative
interventions to best improve psychiatric disease outcomes. The methods are much simpler than
others, and have the advantage of being transparent.
Background
There are a number of potential interventions in psychia-
try that would help improve patient outcomes. The prob-
lem is how to decide which ones to prioritise for service
development. While measures, such as Number Needed
to Treat (NNT) and Quality Adjusted Life Years (QALY),
do provide estimates of the benefit of interventions, they
do not allow impact at the population level to be quanti-
fied. We have developed a new set of Population Impact
Measures (PIMs) to describe the population impact of
risks and benefits [1-4]. Population Impact Measures are
simple to compute, and contain the elements to which
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policy-makers would have to pay attention in the com-
missioning or improvement of services. For describing the
population impact of an intervention, the Number of
Events Prevented in a Population (NEPP)[2] describes the
impact of treatment or other interventions and is defined
as "the number of events prevented by the intervention in your
population over a defined time period".
The measure NEPP is a population extension of the well-
known Number Needed to Treat (NNT), and takes into
account the frequency of the condition in the population
and the proportion of those with the condition who are
actually exposed to the intervention. The measure pro-
vides local context to previous measures, allowing policy-
makers to identify and prioritise the potential benefits of
interventions on their own population. This paper derives
NEPP for interventions used in two important psychiatric
conditions, and demonstrates the potential for helping to
prioritise interventions to make maximal impact on the
population.
Methods
We have obtained literature-based estimates of the com-
ponents required to calculate the NEPP for a number of
different interventions for schizophrenia and for depres-
sion. There are a number of relevant practice guidelines in
the UK [5-7], and in the US [8,9], but none of them give
an idea of the benefit to a particular population. The
NEPP can be used to estimate the incremental impact of
moving from current to best practice and is calculated as
shown in Table 1.
We chose to examine the population impact of interven-
tions recommended in the NICE guidelines for depression
[10] and schizophrenia [11] wherever we could identify
data to make the calculations, for a notional population
of 100,000 adults. Thus for depression, we examined con-
tinuing treatment with antidepressant therapy, screening
to increase the rate of diagnosis, and cognitive behaviour
therapy (CBT). We also included increasing care manage-
ment as there are a number of relevant trials. For schizo-
phrenia, we examined intervention by an early
intervention team, increasing adherence to drug treat-
ment, and family and relapse prevention interventions.
We were unable to find appropriate data for CBT, assertive
outreach, crisis resolution or home treatment teams. We
chose hospitalisation and relapse as outcomes with differ-
ent perspectives, although since hospitalisation is rare in
depression and not used in most trials, we restricted the
use of this outcome to schizophrenia. Table 2 lists the
interventions which we included, and those we excluded,
in our analysis.
The data on prevalence and evidence on effectiveness
come from a review of a number of papers, some are sys-
tematic reviews and some are individual trials. Where dif-
ferences in estimates are found between publications, an
estimate that represents the consensus has been
Table 1: Formula for calculating Number of Events Prevented in your Population (NEPP)
NEPP = n * Pd * Pe * ru * RRR 
where
n = population size
Pd = the prevalence of the disease in the population
Pe = the proportion eligible for treatment
ru = the risk of the event of interest in the untreated group or baseline risk
RRR = the relative risk reduction associated with the treatment
In order to reflect the incremental effect of changing from current to 'best' practice and to adjust for levels of compliance the proportion eligible for 
treatment Pe is ((Pb - Pt) * Pc where Pt is the proportion currently treated, Pb is the proportion that would be treated if best practice was adopted and 
Pc is the proportion of the population who are compliant with (adherent to) their medication.
Table 2: Interventions included in the NICE recommendations which were included (or excluded) in this analysis
Depression:
• Continuing treatment with antidepressant therapy
• Screening to increase the rate of diagnosis
• Cognitive behaviour therapy (CBT)
• Increasing care management (not included in NICE recommendations, but evidence found)
Schizophrenia
• Early intervention
• Increasing adherence to drug treatment
• Family intervention
• Relapse prevention
CBT, assertive outreach, crisis resolution or home treatment teams not included as no evidence for benefit foundClinical Practice and Epidemiology in Mental Health 2006, 2:3 http://www.cpementalhealth.com/content/2/1/3
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attempted, using median or mean values depending on
the data.
Since we have had to use estimates for many of the varia-
bles, we have performed a one-way sensitivity analysis
[12,13] to explore the differences that would have been
seen with the use of different estimates. We calculated the
NEPP for the minimum and maximum of each parameter
while holding the other parameters constant. For the rela-
tive risk reduction we used the lower and upper limits of
the 95% confidence interval as the minimum and maxi-
mum estimates. We used the minimum of the minimum
estimates and the maximum of the maximum estimates as
our interval of plausible values for the NEPP.
Results
Depression
The prevalence of major depression was taken from Kes-
sler [14] at 6.6%, although estimates ranged from 5% [15]
to 8%[13]. Since only 48% of patients currently have their
depression diagnosed (taken from 45%[13] and 51%
[14], we have adjusted the prevalence estimates to those
currently diagnosed, and used the converse for the esti-
mates of the prevalence of undiagnosed depression. The
outcome of 'relapse' was used (1-year wherever possible),
since hospitalisation is rare in this condition, and most
trials did not report it. Where relapse was not used, but
'remission' reported, the converse of remission was
assumed to represent relapse. The baseline risk of relapse
ranged from 41%[16] to 65%[13], and we took 50% as
our estimate. The proportion of the population currently
receiving each intervention was obtained from various
sources. We assumed that 50% of patients are currently
receiving continuing treatment with anti-depressants, and
only 5% currently have increased care management and
Cognitive Behaviour Therapy (CBT). Best practice inter-
vention goals are assumed to be 75% for each interven-
tion. Compliance/adherence with each intervention is
taken as 82% for continuing treatment with anti-depres-
sants[16], and 60% (from 66% [17] and 51% [18] for
increasing care management. We have used 58% for com-
pliance with CBT, based on a summary of the various data
sources we could find [19-21].
For increasing the diagnosis of depression, we assumed
that we would identify 84% of those previously undiag-
nosed (being the sensitivity of the screening instru-
ment[13] and that 63% would be compliant with the
medication started as a result of the screening diagnosis
[22]. Relative Risk Reduction is taken as 70% for continu-
ing treatment with antidepressants[16], 41% for increas-
ing diagnosis (from relative benefits of 1.6 and 1.7 for
pharmacotherapy in comparison with placebo [23], 15%
increasing care management (taken from Odds Ratios of
1.9 for remission [24], and 50% for CBT (50% relapse rate
reduction compared with antidepressants [25] and 66%
in recurrent depression [26]). These data are summarised
in Table 3.
Schizophrenia
Prevalence is estimated as 3/1000 population, consistent
with data from three reports [27-29], although this
Table 3: Depression: data used for the calculations. Figures are percentages (range).
Treatment Continuing treatment with 
antidepressants




Prevalence of depression 3.2* (2.6,3.8) 3.4** (2.9,4.2) 3.2* (2.6,3.8) 3.2* (2.6,3.8)
Outcome Relapse Relapse Relapse Relapse
Baseline risk of outcome (relapse) in 
next year
50 (41,65) 50 (41,65) 50 (41,65) 50 (41,65)
Percentage of those with the disease 
currently receiving treatment 
(or diagnosis)
50 0 5 5
'Best practice' treatment 
(or diagnosis) goal
75 75 75 75
Compliance with treatment 
(or diagnosis)
82 (30,97) 84x63 60 (51,66) 58 (47,79)
Relative Risk Reduction associated 
with the treatment
70 (62,78) 41 (23,56) 15 (1,27) 50 (34,64)
Numbers of Events Prevented in the 
Population, and (95% Confidence 
Intervals), by each intervention in the 
next year among a population of 
100,000, going from current to 'best' 
practice
227 (83,295) 279 (157,381) 100 (7,180) 325 (219,442)
* prevalence (%) currently diagnosed
** prevalence (%) currently un-diagnosedClinical Practice and Epidemiology in Mental Health 2006, 2:3 http://www.cpementalhealth.com/content/2/1/3
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includes a variety of clinical states and will vary according
to demographic variables. We have used two different out-
comes, hospitalisation and relapse, both over 1-year or as
close to it as possible. Relapse is defined differently in dif-
ferent studies [30-33], ranged from 44% to 50%, and we
have used 48%. Hospitalisation ranged from 39% [34] to
50%[30] and 51% [33], and we have used 45%. The pro-
portion currently receiving the intervention was assumed
to be 0 for each of the interventions, with the exception of
increasing adherence to medication, for which 66% was
the current baseline adherence rate in the intervention
arm of trials to increase adherence [35]. The best practice
goal for each intervention was estimated to be 75%, apart
from increasing adherence to medication, where 76%
were adherent after the intervention [35]. Adherence to
the intervention was taken from the intervention arm of
the trials or summaries of trials, and was 76% for early
intervention [33], and estimated as 80% for the other
interventions (although not relevant for the increasing
adherence to medication intervention where adherence
was already taken into account in estimating the best prac-
tice goal). Relative Risk Reductions for relapse and hospi-
talisation respectively were 54% and 52% for early
intervention [33], 50% and 44% for relapse prevention
[34] and 28% for relapse only for family intervention
[31]. Relative Risk Reduction for increasing adherence was
estimated as 45%: 64% (Odds Ratio of 2.8 [36] for
increasing medication adherence) multiplied by the effect
of the medication itself estimated at 70% reduction in
relapse rate (and applied also to re-hospitalisation)[37].
These data are summarised in Table 4.
Number of events prevented
The NEPP for relapse for both depression and schizophre-
nia and hospital re-admission for schizophrenia are also
shown in Tables 3 and 4. In a notional population of
100,000 adults, going from current to 'best' practice for
different interventions, the number of relapses prevented
in the next year for schizophrenia were 6 (increasing
adherence to medication), 23 (family intervention), 43
(relapse prevention), and 44 (early intervention); and for
depression the number of relapses prevented in the next
year were 100 (increasing care management), 227 (con-
tinuing treatment with antidepressants), 279 (increasing
rate of diagnosis), and 325 (Cognitive Behaviour Ther-
apy). Hospital re-admissions prevented in the next year
for schizophrenia were 6 (increasing adherence to medi-
cation), 36 (relapse prevention) and 40 (early interven-
tion).
They demonstrate a large difference in relapses prevented
between depression and schizophrenia, and smaller dif-
ferences between the interventions for each condition.
Table 4: Schizophrenia: data used for the calculations. Figures are percentages (range)
Treatment Early Intervention Team Increase adherence to 
medication
Family intervention Relapse prevention
Prevalence 0.3 (2.3,7.4) 0.3 (2.3,7.4) 0.3 (2.3,7.4) 0.3 (2.3,7.4)








Baseline risk of outcome 
in next year
48 (44,50) 45 (39,51) 48 (44,50) 45 (39,51) 48 (44,50) 45 (39,51) 48 (44,50) 45 (39,51)
Percentage of those with 
the disease currently 
receiving treatment
0 0 66* 66* 0 0 0 0
'Best practice' treatment 
goal
75 75 76 76 75 75 75 75
Compliant with treatment 76 76 N/A N/A 80 80 80 80
Relative Risk Reduction 
associated with the 
treatment
54 (3,78) 52 (3,78) 45 (36,49) 45 (36,49) 28 (15,40) N/A 50 (-7,77) 44 (-10,72)
Numbers of Events 
Prevented in the 
Population, and (95% 
Confidence Intervals), by 
each intervention in the 
next year among a 
population of 100,000, 
going from current to 
'best' practice
44 (2,109) 40 (2,98) 6 (5,16) 6 (5,15) 23 (13,59) N/A 43 (-6,106) 36 (-8,87)
* currently adherent to medicationClinical Practice and Epidemiology in Mental Health 2006, 2:3 http://www.cpementalhealth.com/content/2/1/3
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Discussion
The choice of conditions to examine in this work was dic-
tated by those interventions for which evidence of benefit
was available from a literature review. Some of the inter-
ventions included in guideline recommendations do not
meet this criterion. In the case of CBT in schizophrenia, a
systematic review showed no effect on relapse or re-
admission[38], although some individual trials have
shown an effect [39]. A review of trials of crisis interven-
tion did show an effect, but this was dependent on only
one trial [40]. Where possible, we used systematic reviews,
since individual trials often provide conflicting informa-
tion (as in attempts to increase compliance with therapy
[36,41,42]).
One of the most difficult issues in interpreting the results
of, and comparing between interventions, in the field of
psychiatry, is the decision about which outcome measure
to use [43]. Interventions for different diseases or condi-
tions will have different outcomes. Some may result in an
improvement in mortality, others in morbidity. This has
led to the creation of generic outcome measures, such as
the Quality Adjusted Life Year (QALY) and the Disability
Adjusted Life Year (DALY), which have the advantage of
allowing direct comparison of outcome between different
interventions. They rely on derivation of weights and val-
ues for different disease outcomes, which have been criti-
cised as being arbitrary, although they have been used
extensively in assessments of the cost-effectiveness of
interventions in mental health[28,44-46]. The advantage
of our measures is that they allow the policy-maker to see
exactly which outcomes are being affected. For example, a
hospital manager might prioritise the prevention of hos-
pital re-admissions, while a patient or carer might be
more interested in symptom relapse. The use of various
measures depends on which ones have been included in
the studies contained in the evidence base, which vary
between study and condition.
Use of Population Impact Measures (PIMs), allows a pop-
ulation perspective to the estimate of risks and benefits. If
an intervention is effective in individuals, but the condi-
tion it is used to treat is uncommon in your own popula-
tion, its impact on the population will be more limited
than an alternative intervention with lower effectiveness
but which can be used on a larger proportion of the pop-
ulation. The findings here demonstrate the different pop-
ulation impact of interventions for conditions of different
prevalence in the population. We see from Tables 3 and 4,
that the numbers of relapses prevented by each of the
interventions for depression are much higher than those
for schizophrenia. The differences in population impact
between interventions for depression and schizophrenia
reflect the difference in prevalence between the two, con-
sistent with estimates by Andrews[44]. Whether there is a
real choice to be made between depression and schizo-
phrenia is debatable, since, at least in the UK, the respon-
sibility for those in the population with depression is
mainly shouldered by primary care whereas specialist psy-
chiatric services are the agencies mostly responsible for
delivery of care for people with schizophrenia[47]. It is
also difficult to compare relapse in the two conditions.
Since hospitalisation is rare in depression, we cannot
compare hospitalisations between the two conditions.
Within-condition comparisons between different inter-
ventions may allow the policy-maker to prioritise between
them. We see large differences in population impact
between different interventions although the range of
impact indicated by the sensitivity analysis demonstrates
how susceptible these measures are to variation in the
parameter estimates on which they are based.
Another advantage of the use of Population Impact Meas-
ures, is that they provide an estimate in a particular popu-
lation, of going from current to 'best' practice. The
numbers are thus dependent on current practice levels
and the treatment goals. Where the goals are close to cur-
rent practice, the potential population gain will be lower
than where the gap is large, due either to poor current
practice or ambitious goals. The potential impact thus can
be personalised to the individual population into which
the intervention is to be introduced. The results we
present will thus vary according to local settings. Although
the data used here come from a UK setting, the method is
fully transportable to other populations.
Although cost data would be needed to make a final pri-
oritisation decision, we have deliberately left the out-
comes to be expressed in the terms in which the data were
collected (rather than the generic measures used in cost-
effectiveness estimates) so that benefit expressed as real
outcomes can be identified. A subsequent step would be
to prioritise between interventions, taking costs into
account, once the population impact can be observed.
The estimates we have made depend on the availability of
relevant data. We have used literature-based estimates,
which in themselves vary considerably. For example,
adherence to drug treatment for depression varied from
30 to 97% in a number of trials, with a median of 63%
[22]. We have used a different value for adherence to con-
tinuing drug treatment for depression (82%), based on the
non-withdrawal rate from trials in a systematic
review[16]. The estimates used in this paper for adher-
ence, both to medication and to adherence enhancing
interventions, may thus not relate to local practice set-
tings. Similarly, access to non-pharmaceutical interven-
tions will vary considerably. Depending on the definition
used, in the UK, there may be 20 times more CBT practi-
tioners per population in the best provided 10% of theClinical Practice and Epidemiology in Mental Health 2006, 2:3 http://www.cpementalhealth.com/content/2/1/3
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population than in the worst 10%, and our estimate of
5% of current exposure to CBT for depression is greater
than the 1% national estimate of availability to those who
might benefit [48]. The accuracy of the estimates would be
increased by better availability of local data from the pop-
ulation to which they would be applied, and the gaps in
the data necessary for the preparation of this paper dem-
onstrate a clear need for better relevant data. However, it
should be noted that local data may be plagued by small
numbers causing under-ascertainment of prevalence and
outcomes. The need for good local data should motivate
improvements in local data collection systems. If good
local data were available, the variability in the NEPP
would only be due to variability in measures of risk and
RRR and where good meta-analyses exist the RRR estimate
is relatively stable. The method could also be adapted to
explore the benefits of policy changes such as those
designed to prevent suicide, however, this will depend on
obtaining some estimate of benefit. A previous paper esti-
mated population attributable fractions for alternative
strategies for preventing suicide, and recommended pop-
ulation-based rather than high-risk strategies as a result
[49]. This methodology is a fore-runner to ours, which
allows 'personalisation' to the local population into
which the strategy is to be introduced. We have not
explored the impact of different population demographic
structures or severity case-mix in this paper, but the impli-
cations for a local population will depend on the features
that determine prevalence, treatment patterns and base-
line risk of disease.
Conclusion
The use of Population Impact Measures provides the pos-
sibility for a policy-maker to see the impact of a new inter-
vention on the population as a whole and to compare
alternative interventions. Our methods are much simpler
than those which use generic outcomes such as the QALY
[28,44,45], and have the advantage of being transparent.
We believe that not only will their use assist in priority set-
ting, but that their transparency will allow the policy-
maker to identify gaps in the availability of local (and
trial) data – information which is essential if an evidence
base is to be used to prioritise interventions based on
improving the health of the population [50].
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